Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [2510]

Huntington's disease provides new cancer weapon

Huntington's disease provides new cancer weapon

New immunotherapy combination tolerable, effective in patients with advanced kidney cancer

New immunotherapy combination tolerable, effective in patients with advanced kidney cancer

FDA approves abiraterone acetate in combination with prednisone for high-risk metastatic castration-sensitive prostate cancer

FDA approves abiraterone acetate in combination with prednisone for high-risk metastatic castration-sensitive...

ASCO GU 2018: Opening new therapeutic avenues in metastatic prostate cancer

ASCO GU 2018: Opening new therapeutic avenues in metastatic prostate cancer

ASCO GU 2018: Apalutamide delays prostate cancer metastases by more than two years

ASCO GU 2018: Apalutamide delays prostate cancer metastases by more than two years

ASCO GU 2018: Adding immunotherapy to standard treatment slows growth of advanced kidney cancer, with fewer side effects

ASCO GU 2018: Adding immunotherapy to standard treatment slows growth of advanced kidney cancer, with fewer side...

ASCO GU 2018: Chemotherapy added to hormone therapy for prostate cancer improves quality of life

ASCO GU 2018: Chemotherapy added to hormone therapy for prostate cancer improves quality of life

ASCO GU 2018: New model predicts survival for people with bladder cancer receiving immunotherapy

ASCO GU 2018: New model predicts survival for people with bladder cancer receiving immunotherapy

PSMA PET/CT visualises prostate cancer recurrence early, impacts radiation therapy

PSMA PET/CT visualises prostate cancer recurrence early, impacts radiation therapy

Cell signalling and support networks: Mobile phones in cancer and care

Cell signalling and support networks: Mobile phones in cancer and care

More from ecancer